spirogermanium has been researched along with etoposide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auber, ML; Blaauw, A; Dicke, KA; Horwitz, LJ; Khorana, S; McCredie, KB; Spitzer, G; Tucker, S; Warmuth, M; Woods, T | 1 |
| Asbury, RF; Cnaan, A; Haller, DG; Harris, J; Johnson, L; Zaentz, SD | 1 |
| Asbury, R; Dutcher, JP; Haller, DG; Novik, Y; Ryan, LM; Schutt, A | 1 |
2 trial(s) available for spirogermanium and etoposide
| Article | Year |
|---|---|
An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer.
Topics: Aclarubicin; Adenocarcinoma; Adjuvants, Immunologic; Antineoplastic Agents; Etoposide; Female; Humans; Male; Mitoxantrone; Organometallic Compounds; Pancreatic Neoplasms; Spiro Compounds; Survival Rate | 1994 |
Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.
Topics: Aclarubicin; Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Male; Mitoxantrone; Organometallic Compounds; Spiro Compounds; Stomach Neoplasms | 1999 |
1 other study(ies) available for spirogermanium and etoposide
| Article | Year |
|---|---|
Evaluation of drugs for elimination of leukemic cells from the bone marrow of patients with acute leukemia.
Topics: Antineoplastic Agents; Asparaginase; Bleomycin; Bone Marrow; Cyclophosphamide; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Etoposide; Hydrocortisone; Leukemia, Lymphoid; Organometallic Compounds; Spiro Compounds; Tumor Cells, Cultured; Vincristine | 1988 |